Literature DB >> 21389871

Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells.

Jeffrey L Wong1, Robbie B Mailliard, Stergios J Moschos, Howard Edington, Michael T Lotze, John M Kirkwood, Pawel Kalinski.   

Abstract

Natural killer (NK) cells have been shown to mediate important immunoregulatory "helper" functions in addition to their cytolytic activity. In particular, NK cells are capable of preventing maturation-related dendritic cell (DC) "exhaustion," inducing the development of "type-1 polarized" mature DCs (DC1) with an enhanced ability to produce interleukin (IL)-12p70, a factor essential for type-1 immunity and effective anticancer responses. Here we show that the NK cell-mediated type-1 polarization of DCs can be applied in the context of patients with advanced cancer to enhance the efficacy of DCs in inducing tumor-specific cytotoxic T lymphocytes. NK cells isolated from patients with late-stage (stage III and IV) melanoma responded with high interferon-γ production and the induction of type-1-polarized DCs on exposure to defined combinations of stimulatory agents, including interferon-α and IL-18. The resulting DCs showed strongly-enhanced IL-12p70 production on subsequent T-cell interaction compared with immature DCs (average of 19-fold enhancement) and nonpolarized IL-1β/TNF-α/IL-6/PGE(2)-matured "standard" DCs (average of 215-fold enhancement). Additional inclusion of polyinosinic: polycytidylic acid during NK-DC cocultures optimized the expression of CD80, CD86, CD40, and HLA-DR on the resulting (NK)DC1, increased their CCR7-mediated migratory responsiveness to the lymph node-associated chemokine CCL21, and further enhanced their IL-12-producing capacity. When compared in vitro with immature DCs and nonpolarized standard DCs, (NK)DC1 were superior in inducing functional melanoma-specific cytotoxic T lymphocytes capable of recognizing multiple melanoma-associated antigens and killing melanoma cells. These results indicate that the helper function of NK cells can be used in clinical settings to improve the effectiveness of DC-based cancer vaccines.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21389871      PMCID: PMC3057371          DOI: 10.1097/CJI.0b013e31820b370b

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  62 in total

1.  The concept of type 1 and type 2 antigen-presenting cells.

Authors:  M L Kapsenberg; P Kalinski
Journal:  Immunol Lett       Date:  1999-06-15       Impact factor: 3.685

2.  Final maturation of dendritic cells is associated with impaired responsiveness to IFN-gamma and to bacterial IL-12 inducers: decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells.

Authors:  P Kaliński; J H Schuitemaker; C M Hilkens; E A Wierenga; M L Kapsenberg
Journal:  J Immunol       Date:  1999-03-15       Impact factor: 5.422

Review 3.  Dendritic cells and the control of immunity.

Authors:  J Banchereau; R M Steinman
Journal:  Nature       Date:  1998-03-19       Impact factor: 49.962

Review 4.  Tolerance, danger, and the extended family.

Authors:  P Matzinger
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

5.  Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells.

Authors:  R M Verdijk; T Mutis; B Esendam; J Kamp; C J Melief; A Brand; E Goulmy
Journal:  J Immunol       Date:  1999-07-01       Impact factor: 5.422

6.  Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming.

Authors:  Alfonso Martín-Fontecha; Lindy L Thomsen; Sara Brett; Craig Gerard; Martin Lipp; Antonio Lanzavecchia; Federica Sallusto
Journal:  Nat Immunol       Date:  2004-11-07       Impact factor: 25.606

7.  Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12.

Authors:  Y Nishioka; M Hirao; P D Robbins; M T Lotze; H Tahara
Journal:  Cancer Res       Date:  1999-08-15       Impact factor: 12.701

8.  Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors.

Authors:  L Zitvogel; P D Robbins; W J Storkus; M R Clarke; M J Maeurer; R L Campbell; C G Davis; H Tahara; R D Schreiber; M T Lotze
Journal:  Eur J Immunol       Date:  1996-06       Impact factor: 5.532

9.  Differentiation of human NK cells into NK1 and NK2 subsets.

Authors:  D Peritt; S Robertson; G Gri; L Showe; M Aste-Amezaga; G Trinchieri
Journal:  J Immunol       Date:  1998-12-01       Impact factor: 5.422

10.  Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites.

Authors:  M C Dieu; B Vanbervliet; A Vicari; J M Bridon; E Oldham; S Aït-Yahia; F Brière; A Zlotnik; S Lebecque; C Caux
Journal:  J Exp Med       Date:  1998-07-20       Impact factor: 14.307

View more
  21 in total

Review 1.  NK cells: key to success of DC-based cancer vaccines?

Authors:  Eva Lion; Evelien L J M Smits; Zwi N Berneman; Viggo F I Van Tendeloo
Journal:  Oncologist       Date:  2012-08-20

2.  IL-18 genetic polymorphisms may contribute to the pathogenesis of tuberculosis among Asians: a meta-analysis of case-control studies.

Authors:  Xiao-Ling Yu; Fei Zhao; Jun Zhang; Xiao-Ming Pan
Journal:  Mol Biol Rep       Date:  2014-06-27       Impact factor: 2.316

3.  IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment.

Authors:  Jeffrey L Wong; Erik Berk; Robert P Edwards; Pawel Kalinski
Journal:  Cancer Res       Date:  2013-06-12       Impact factor: 12.701

4.  Elevated VEGF-A & PLGF concentration in aqueous humor of patients with uveal melanoma following Iodine-125 plaque radiotherapy.

Authors:  Meng-Xi Chen; Yue-Ming Liu; Yang Li; Xuan Yang; Wen-Bin Wei
Journal:  Int J Ophthalmol       Date:  2020-04-18       Impact factor: 1.779

5.  Evaluation of the Functional Capacity of NK Cells of Melanoma Patients in an In Vitro Model of NK Cell Contact with K562 and FemX Tumor Cell Lines.

Authors:  Gordana Konjevic; Ana Vuletic; Katarina Mirjacic Martinovic; Ana Krivokuca; Radmila Jankovic; Nada Babovic
Journal:  J Membr Biol       Date:  2017-09-08       Impact factor: 1.843

6.  Synergistic COX2 Induction by IFNγ and TNFα Self-Limits Type-1 Immunity in the Human Tumor Microenvironment.

Authors:  Jeffrey L Wong; Nataša Obermajer; Kunle Odunsi; Robert P Edwards; Pawel Kalinski
Journal:  Cancer Immunol Res       Date:  2016-01-27       Impact factor: 11.151

7.  Human NK cells prime inflammatory DC precursors to induce Tc17 differentiation.

Authors:  Maria A Clavijo-Salomon; Rosalba Salcedo; Soumen Roy; Rodrigo X das Neves; Amiran Dzutsev; Helioswilton Sales-Campos; Karen Steponavicius-Cruz Borbely; Lucia Silla; Jordan S Orange; Emily M Mace; José A M Barbuto; Giorgio Trinchieri
Journal:  Blood Adv       Date:  2020-08-25

8.  IL-18 Responsiveness Defines Limitations in Immune Help for Specialized FcRγ- NK Cells.

Authors:  Renee R Anderko; Charles R Rinaldo; Robbie B Mailliard
Journal:  J Immunol       Date:  2020-11-13       Impact factor: 5.422

Review 9.  Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs.

Authors:  Cristina Capuano; Chiara Pighi; Simone Battella; Davide De Federicis; Ricciarda Galandrini; Gabriella Palmieri
Journal:  Cancers (Basel)       Date:  2021-05-20       Impact factor: 6.639

10.  GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo.

Authors:  Okjae Lim; Yuna Lee; Hyejin Chung; Jung Hyun Her; Sang Mi Kang; Mi-young Jung; Bokyung Min; Hyejin Shin; Tae Min Kim; Dae Seog Heo; Yu Kyeong Hwang; Eui-Cheol Shin
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.